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Abstract: This study sought to characterize the experience of stress, treatment patterns, and 
medical and disability profile in the migraineur population to better understand how the experi-
ence of migraines impacts the social and psychological functioning of this group. A 30-minute 
self-report survey was presented via a migraine-specific website with data collection occur-
ring between May 15 and June 15, 2012. Recruitment for the study was done through online 
advertisements. In total, 2,907 individuals began the survey and 2,735 met the inclusion criteria 
for the study. The sample was predominantly female (92.8%). Migraine-associated stress was 
correlated with length of time since first onset of symptoms (P,0.01) and number of symptoms 
per month (P,0.01). Disorders related to stress, such as depression (P,0.01) and anxiety 
(P,0.01), were also positively correlated with the measured stress resulting from migraines. 
Migraine-associated stress must be understood as a multidimensional experience with broader 
impacts of stress on an individual correlating much more highly with negative mental and 
physical health profiles. Stress resulting from frequent migraine headaches may contribute to 
the development of medical and psychological comorbidities and may be a part of a cyclical 
relationship wherein stress is both a cause and effect of the social and medical impairments 
brought about by migraine.
Keywords: characteristics, migraine, headache, stress, treatment satisfaction
Introduction
Migraine headache is a chronic pain condition that afflicts millions of Americans, with 
prevalence estimates ranging between 16.2% and 22.7% for USA adults aged 18 years or 
older.1 Migraines are disabling, with a majority of migraineurs reporting impairments in 
their ability to engage in work activities, perform household chores, attend social activi-
ties, and maintain relationships due to their migraines.2 The social costs of migraine are 
felt in the form of lost productivity as well as increased health care costs.3 The disorder 
is further complicated by the multiple and varied symptoms that have been reported, 
including sweating, allodynia, photophobia, phonophobia, vomiting, and nausea.4
In light of the high prevalence rate and significant impairment of daily living, it is 
unsurprising that patients use many treatment approaches to alleviate the impact of 
migraine. Pharmacological treatments are common, with both abortive and prophylactic 
medications used; however, these medications are burdened by side effects and cost.5 
Non-pharmacological interventions, such as behavioral therapy,6 relaxation therapy, 
and cognitive behavioral therapy, have also been employed, with varying degrees of 
success.5 Despite the variety of treatment approaches available, migraineurs report 
that they feel their treatment is insufficient or unsatisfactory.7
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Frequent migraine headaches also impose a heavy 
psychological burden on migraineurs. Both stress and 
anxiety levels are higher among migraineurs when com-
pared with healthy controls.8 Other research has found a 
reinforcing cyclical relationship between stress and migraine 
headaches.9 The relationship between stress and migraine 
may also have a deeply personal component, as suggested 
in recent findings, ie, an individual’s response to stressors, 
rather than the stressors themselves, may be the predispos-
ing factor to developing migraine.10 Previous research has 
treated the experience of stress in the context of migraine 
headache as principally a prodromal indicator of onset of 
migraine and a strictly internal experience on the part of 
the migraineur.8
The experience of migraines is further complicated by 
comorbid medical and psychological disorders. Psychological 
disorders, especially depression and anxiety, have been found 
to be prevalent among migraineurs.2 Chronic pain, stroke, 
gastrointestinal disorders, cardiovascular disease, and other 
medical conditions have also been found to be more prevalent 
in migraineurs compared with the general population.11 Given 
the high prevalence of migraine headaches, it is unsurprising 
that a large variety of comorbid medical and psychological 
disorders is found in the migraine population.
The high social and personal costs of migraine as well 
as complications in delivering effective migraine treatment 
emphasize the need to understand treatment patterns in 
this highly prevalent clinical population. The current study 
extends the available literature by describing the relation-
ship between stress, treatment patterns and satisfaction, and 
comorbid disorders in a large online sample of migraineurs. 
This study elaborates on previous research into migraine-
associated stress by viewing the stress experience as a social 
as well as internal impact of migraine headaches.
Patients and methods
Recruitment
Participants were recruited from a well-known online 
migraine headache resource. Adults aged 18 years or older 
and currently living in the USA were invited to participate. 
The presence of migraines was validated through agreement 
with the statement “Have you ever been diagnosed with 
migraine headaches by a physician?”
Procedure
This study was approved by the University of Massachusetts 
institutional review board. Between May 15 and June 15 
2012, an online survey was presented via a migraine-specific 
community website.12 Participants were informed that 
their participation was voluntary, information would be 
collected anonymously, the anticipated completion time of 
the survey, and that they would not receive compensation 
for participating. No personal identifiers were collected nor 
solicited from participants. The survey contained questions 
related to demographic information, migraine history and 
symptoms, social information, and treatment history and 
satisfaction. The survey host used embedded cookies to 
prevent any participant from taking the survey multiple 
times. The survey employed an adaptive methodology. 
Data were collected by the survey host and stored on a 
secure server.
A composite variable termed “negative live events” 
was created using items from the survey that examined 
specific areas of life impacted by participant migraineurs. 
The negative life events score was further divided into vari-
ables examining internal areas of life, such as mental state 
and well-being, and external areas of life, such as social 
relationships.
Data analysis
All data analysis was performed using Statistical Package for 
the Social Sciences version 22.0 (IBM Corporation, Armonk, 
NY, USA). Participant demographics were analyzed using 
descriptive statistics and analysis of variance, and Pearson’s 
R correlation analyses were used to examine relationships 
among the survey data. Path analyses were conducted to 
examine differential relationships among the length of time 
since onset of migraine symptoms, the number of reported 
comorbidities, the frequency of migraine symptoms, the 
number of migraine symptoms, and composite scores reflect-
ing impacts resulting from migraines (negative life impact 
internal score and negative life impact external score).
Results
Participants
The survey was started by 2,907 individuals. A total of 
172 individuals were excluded due to: being younger than 
18 years (n=32), not diagnosed with migraines (n=19), or 
not currently living in the USA (n=121). Of the remaining 
2,735 individuals who started the survey, 2,632 completed 
it (giving a completion rate of 96.2%). The mean time taken 
to complete the survey was 23 minutes (± standard deviation 
1 minute 25 seconds). Due to the use of adaptive survey 
methodology, participants did not answer questions that 
were not pertinent to them, resulting in a small variation in 
the number of responses per question.
Journal of Pain Research 2015:8
Table 1 Patient demographics and disease characteristics
Patient,  n (%)
sex 
Male 
Female
 
196 (7.2) 
2,514 (92.8)
age, years 
,18 
18–24 
25–39 
40–54 
.55
 
18 (excl)* 
190 (6.9) 
921 (33.7) 
1,307 (47.8) 
317 (11.6)
Length of time since first migraine symptoms 
,1 year 
1–5 years 
6–10 years 
10+ years
 
38 (1.4) 
267 (9.9) 
349 (12.9) 
2,056 (75.9)
Usa resident 
Yes 
no
 
2,735 (95.6) 
121 (excl)*
Days per month migraine symptoms $4 hours (n) 
1–4 
5–9 
10–14 
15–19 
20+
 
464 (17.1) 
564 (20.8) 
513 (18.9) 
488 (18.0) 
681 (25.1)
ever diagnosed with migraine by physician 
Yes 
no
 
2,503 (98.2) 
19 (excl)*
ever been diagnosed with chronic migraine 
Yes
 
1,709 (68.3)
Note: *These patients were not included in the percentage basis for the final analyses.
Abbreviation: excl, excluded.
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Demographics
The sample was 92.8% female and nearly half of the sample 
(47.8%) was aged 40–54 years, which is demographically 
similar to national rates for migraineurs. The majority of the 
sample (75.9%) had experienced their migraine symptoms 
for more than 10 years. The majority of the sample (68.3%) 
was diagnosed with chronic migraine. A quarter of the 
sample (25.1%) reported experiencing migraine symptoms 
on more than 20 days per month; the remainder of the sample 
experienced migraine symptoms less frequently. Additional 
demographic information can be found in Table 1.
comorbid disorders
Table 2 shows the data relating to reported comorbid disorders. 
Depression and anxiety were found to be the most commonly 
reported comorbid conditions, at 63.8% and 60.4%, respectively. 
Chronic (non-headache) pain was reported by 39.5% of the 
sample. All remaining disorders were reported by less than one-
third of the sample. A minority of participants (16.4%) reported 
suffering from a disorder not listed, and of those participants, the 
vast majority reported multiple comorbid disorders (89.9%).
negative life events
Nearly three quarters (74.1%) of the sample reported that peo-
ple in their social network do not believe that the migraines 
are as severe as the participants report. The migraineurs 
reported that their employer knew about their migraines 
(54.8%) and the migraines negatively impacted their profes-
sional advancement (50.2%).
A composite variable was created by summing the num-
ber of negative life events that participants endorsed in order 
to examine the extent to which migraine headaches impact 
their life (Cronbach’s α=0.848). The negative life event score 
was found to have a mean of 4.023 (standard deviation 27; 
median 4; range 0–13). The results of questions identifying 
the impact of migraine on personal aspects of life can be 
found in Table 3.
 The negative events were also examined according to 
whether the migraineurs perceived that the negative impact 
was caused by internal (psychoemotional) stress factors or 
external (social-interactive) stress factors. The negative life 
impact internal score was composed of questions asking 
about the migraineurs’ feelings of worry or shame about 
their migraine headaches. The negative life impact external 
score was composed of questions examining the social, 
professional, and relational impact of migraines. Pearson’s R 
correlational coefficient path analyses examining the relation-
ship between the characteristics of migraine and the internal 
Table 2 comorbid disorders
Comorbid disorder Patient, n (%)
Depression 1,411 (63.8)
anxiety 1,328 (60.4)
stroke 55 (2.5)
epilepsy 58 (2.6)
hypertension 390 (17.6)
Diabetes 124 (5.6)
Bipolar 145 (6.6)
iBs 647 (29.3)
chronic pain 874 (39.5)
Fibromyalgia 360 (16.3)
Thyroid disease 357 (16.1)
chronic fatigue 574 (26.0)
asthma 441 (19.9)
cOPD 51 (2.3)
autoimmune disorder 116 (5.2)
any comorbid disorder reported 476 (16.4)
Reported comorbidities 
  1 
2 
3 
4 
5 
6–11
 
338 (71.0) 
90 (18.9) 
28 (5.9) 
12 (2.5) 
5 (1.1) 
3 (0.6)
Abbreviations: cOPD, chronic obstructive pulmonary disease; iBs, irritable bowel 
syndrome.
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of participants who were found to have a negative life event 
score of 10 or higher also reported 15 or more migraine 
symptoms per month.
Migraine triggers
Most of the participants (78.2%) were able to identify at least 
one trigger for their migraine headaches. Of those participants 
who did identify a trigger, 78.3% identified environmental 
causes (such as weather) and 76.7% identified stress as a 
trigger. Of those participants who identified triggers for their 
migraines, 88.3% reported that they take steps to avoid those 
triggers. Additional results are reported in Table 5.
Migraine treatments
In total, 96.7% of the sample reported consulting a physician 
specifically for treatment of migraine headaches at some 
point and 81.3% of the sample were currently seeing a physi-
cian about their migraine (Figures 3, 4 and Table 6). Of those 
who do not see a physician about migraine, 47.7% reported 
financial cost or health insurance to be the preventing fac-
tor. Approximately half of the sample (45.5%) reported that 
they avoided taking a prescribed migraine medication due 
to the cost. Ninety percent of the sample reported trying a 
prescription oral migraine medication at some point and 
67.2% reported currently being treated with a prescription 
oral migraine medication. Approximately three quarters of 
the sample (73.3%) reported withholding  medication to 
save for later. Participants also reported behavioral therapies 
Onset of
first
migraine
symptoms
R=0.476
R=0.277
R=0.094
R=0.311
R=0.426
R=0.029 R=0.007
R=0.231
R=0.074
Number of
migraine symptoms
Medical
comorbidities (n)
Number of
psychological/psychiatric
comorbidities
Frequency
of migraine
symptoms
Negative
life
impact:
internal
total score
Figure 1 Path analysis of negative internal life impacts.
Table 3 negative life events
Event Patient, n (%)
People don’t believe my migraines are severe 1,782 (74.1)
i am constantly worried about disappointing people 1,381 (57.4)
employer knows that i suffer from migraines 1,474 (54.8)
impacted my professional advancement 1,207 (50.2)
Migraines affect my ability to maintain relationships 1,027 (42.7)
Migraines impact my relationship with my  
child/children
1,029 (42.8)
i feel like others blame me for my migraines 966 (40.2)
sometimes i blame myself for my migraines 874 (36.4)
Friends/family/colleagues treat me differently because  
of my migraines
807 (33.6)
Doctors treat me differently because of my migraines 747 (31.1)
embarrassed 613 (25.5)
i have lost a job due to migraines 612 (25.5)
i have lost friends due to my migraines 476 (19.8)
Migraines contributed to my divorce/separation 183 (7.6)
and external impacts of migraine can be found in Figures 1 
and 2. Positive correlations were found between all examined 
variables and both the negative life impact internal score and 
negative life impact external score.
Migraine frequency and symptoms
Migraine frequency data can be found in Table 4. The most 
commonly reported symptoms of migraine experienced by 
the sample were head pain (98.0%) and sensitivity to light 
(91.1%). Participants who reported a higher frequency of 
migraine symptoms were also more likely to report more 
negative life impact due to migraine. Seventy-five percent 
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Figure 2 Path analysis of negative external life impacts.
Table 4 Migraine symptom frequency
Days per month impacted by headache symptoms for $4 hours, patients, n (%)
1–4 5–9 10–14 15–19 20+ Total
sex
Male 50 (25.5) 37 (18.9) 36 (18.4) 22 (11.2) 51 (26.0) 196 (7.2)
Female 414 (16.5) 527 (21.0) 477 (19.0) 466 (18.5) 630 (25.1) 2,514 (82.8)
symptom
head pain 419 (16.4) 532 (20.8) 487 (19.1) 471 (18.5) 643 (25.2) 2,552 (98.0)
sensitivity to light 400 (16.8) 476 (20.1) 455 (19.2) 440 (18.5) 603 (25.4) 2,374 (91.1)
sensitivity to sound 339 (15.6) 431 (19.8) 421 (19.4) 410 (18.9) 571 (26.3) 2,172 (83.4)
Difficulty concentrating 299 (14.3) 416 (19.9) 409 (19.6) 392 (18.8) 574 (27.5) 2,090 (80.2)
nausea/vomiting 334 (16.3) 415 (20.3) 388 (19.0) 393 (19.2) 517 (25.3) 2,047 (78.6)
Fatigue 253 (13.0) 401 (20.7) 378 (19.5) 376 (19.4) 533 (27.5) 1,941 (74.5)
neck pain 262 (14.0) 380 (20.2) 346 (18.4) 378 (20.1) 511 (27.2) 1,877 (72.1)
sensitivity to smell 224 (13.6) 312 (18.9) 306 (18.5) 343 (20.8) 465 (28.2) 1,650 (63.3)
Mood changes 197 (12.3) 313 (19.6) 323 (20.2) 330 (20.6) 438 (27.4) 1,601 (61.5)
Dizziness/lightheadedness 216 (13.6) 312 (19.6) 297 (18.7) 313 (19.7) 450 (28.3) 1,588 (61.0)
Migraine aura 286 (19.0) 303 (20.1) 285 (18.9) 280 (18.6) 352 (23.4) 1,506 (57.6)
Visual changes 233 (16.8) 251 (18.0) 262 (18.8) 278 (20.0) 367 (26.4) 1,391 (53.4)
Weakness 169 (14.2) 219 (18.4) 222 (18.7) 235 (19.7) 345 (29.0) 1,190 (45.7)
numbing/tingling 133 (14.6) 133 (14.6) 164 (18.1) 183 (20.2) 295 (32.5) 908 (34.9)
Diarrhea/constipation 86 (10.9) 134 (17.0) 141 (17.9) 178 (22.6) 247 (31.4) 786 (30.2)
Vertigo 87 (11.4) 125 (16.4) 152 (20.0) 150 (19.7) 247 (32.5) 761 (29.2)
Puffy eyelid 58 (9.5) 122 (20.1) 107 (17.6) 135 (22.2) 186 (30.6) 608 (23.2)
Food cravings 44 (8.1)  99 (18.1) 116 (21.4) 123 (22.7) 161 (29.7) 542 (20.8)
negative life event score
low (0–3) 363 (29.4) 335 (27.1) 243 (19.7) 137 (11.1) 158 (12.8) 1,236 (45.6)
Medium (4–9) 96 (7.6) 212 (16.8) 239 (18.9) 295 (23.4) 421 (33.3) 1,263 (46.6)
high (10–13) 5 (2.4) 17 (8.1) 31 (14.7) 56 (26.5) 102 (48.3) 211 (7.8)
that they had tried, with “dark room” (92.2%) and “hot/cold 
therapy” (75.2%) being the most commonly tried; however, 
many participants report initiating a behavioral or comple-
mentary therapy (eg, yoga), but not continuing with the 
practice in the long term.
Treatment satisfaction
When asked about their current migraine treatment, most 
individuals appeared to be less than satisfied with their 
treatment. Approximately one-third of participants (31.2%) 
reported feeling “neutral” on satisfaction and a further 
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27.0% reported being “satisfied” with their current migraine 
treatment (see Figure 5). One-third of respondents (33.7%) 
reported being satisfied with their treating physician and a 
further 29.6% were neutral on their satisfaction with their 
treating physician. Participant satisfaction with behavioral 
or complementary therapies was found to be predominantly 
neutral (38.7%).
Relationship between migraine  
measures and comorbid disorders
The results of the Pearson’s R correlational analyses iden-
tifying relationships between the negative life events score, 
length of time since the onset of migraine symptoms, and 
the monthly frequency of migraine symptoms by presence 
of comorbid disorders can be found in Table 7. The negative 
life events score was found to be significantly correlated 
(P,0.01 or P,0.05) with all comorbid diseases except for 
diabetes and chronic obstructive pulmonary disease. The 
reported length of time since first migraine symptoms was 
found to be significantly correlated (P,0.01) for all disorders 
except stroke and epilepsy. Further, the reported frequency of 
migraine symptoms per month was found to be significantly 
correlated (P,0.01 or P,0.05) for all disorders except for 
stroke. The negative life event score, the length of time since 
onset of migraine, and the monthly frequency of migraine 
symptoms were found to be significantly correlated with each 
other (P,0.01). Additional analyses were conducted accord-
ing to age and sex; however, these analyses were not found 
to be statistically significant. The negative live events score 
was separated into tertiles, ie, high (score 10–13), medium 
(score 4–9), and low (score 0–3) scores. Analyses of vari-
ance comparing these groups found that those in the higher 
tertile group of negative life impact were more likely to have 
a higher frequency of migraine symptoms, a longer history 
of migraine symptoms, and were more likely to experience 
comorbid disorders. The results of these analyses of variance 
can be found in Tables 8–10.
Discussion
The present study characterized migraineurs and examined 
their treatment patterns, stress attributes, migraine disorder 
characteristics, and disability profile. As in previous research 
and clinical data,1 the vast majority of migraineurs in this 
study were female. Respondents in this survey tended to be 
younger than in other large migraine studies, with a higher 
proportion of participants aged 18–39 years but this is most 
likely due to the online mode of delivery rather than a change 
in the migraineur population.13 Similar to previous findings, 
migraineurs at every degree of symptom frequency reported 
that their migraine symptoms negatively affected their lives. 
Migraineurs in this study were found to experience elevated 
levels of bodily pain, anxiety, and depression, and were able 
to identify physiological aspects of their migraines in pro-
portions similar to those in other studies,14 but a substantial 
minority appeared to be ignorant of the prodromal features 
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Figure 3 Rates of current and former treatment usage for migraine.
Table 5 Migraine triggers
Patients, n (%)
Identified triggers that may cause migraines 2,036 (78.2)
stress 1,557 (76.7)
environmental (eg, weather) 1,589 (78.3)
lack of sleep 1,382 (68.1)
hormones/menstrual cycle 1,179 (58.1)
Missing meals 1,096 (54.0)
certain smells 1,058 (52.1)
alcohol/drugs 709 (34.9)
Physical activity 603 (29.7)
sexual activity 165 (8.1)
Other 392 (19.3)
have taken steps to avoid triggers 1,793 (88.3)
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of their condition. This is significant in that while migraine 
headaches commonly confer negative impacts, the precipitat-
ing factors are poorly understood by a large percentage of 
migraineurs, casting doubt on the ability of some patients 
to be knowledgeable about which treatment may be most 
efficacious for them.2,7,15
 Similar to previous findings, migraineurs at every degree 
of symptom frequency reported that their migraine symptoms 
negatively affected their lives. The length of time since the 
participant’s first migraine and the number of migraine 
symptoms were found to have a stronger relationship with 
negative interpersonal and situational impacts than with nega-
tive affective and psychological impacts, such as shame or 
embarrassment related to migraines. While this relationship 
may be a result of misperception of treatment by others or 
poor self-knowledge of emotional state, this observation is 
significant in that it suggests that migraineurs may attribute 
a wide variety of negative social interactions to their disorder 
rather than other factors, such as the dispositions of others 
or situational factors. Previous research has treated the stress 
resulting from migraines as a purely affective or psycho-
logical experience on the part of migraineurs;8 however, our 
research indicates that migraine-associated stress negatively 
impacts social and professional areas even more strongly than 
psychological states. While the findings of this study suggest 
that the negative impacts of migraine related to the number 
and frequency of migraine symptoms may be more closely 
related to the interpersonal impact of migraine, this may not 
be a simple static relationship. It is possible that the inter-
personal impact of migraines may be more easily attributed 
to specific events whereas the self-perceived internal stress 
may result from a general sense derived from recent or 
distant personal experiences. Future research should further 
explore the relationship between the impact of migraines on 
an individual’s social network and the negative affective and 
psychological impacts on migraineurs.
 Despite the fact that the vast majority of the participants 
in this study sought the care of a physician for their migraine 
headaches, only a subset of these participants continued their 
treatment and an even smaller proportion were satisfied or 
extremely satisfied with their treatment. Our study found 
that migraineurs tended to be dissatisfied with their migraine 
treatment regardless of the intervention used. These results 
continue the trend of low patient satisfaction with migraine 
treatment found in previous studies; however, the current 
sample tended to be even more dissatisfied than noted in previ-
ous research.7,16 Similar to previous studies, the current study 
Have you ever seen a physician about your migraines? (n, %)
No (88, 3.3%)Yes (2,560, 96.7%)
Why have you never seen a
physician?
Currently see a physician about
migraines (2,067, 81.3%)
What type of physician have you
ever seen for your migraine?
Obstetrician/gynecologist  (662, 25.9%)
Obstetrician/gynecologist   (99, 4.8%)
Neurologist                         (1,967, 77.1%)
Neurologist                          (1,091, 52.9%)
Headache specialist           (998, 39.1%)
Headache specialist            (486, 23.6%)
Other specialist                  (536, 21.0%)
Other specialist                    (244, 11.8%)
Primary care/internist         (2,307, 90.4%)
Inconvenience/time           (12, 13.6%)
Financial/cost/insurance    (42, 47.7%)
Cannot find the right doctor   (12, 13.6%)
It never occurred to me      (22, 25.0%)
Primary care/internist          (1,153, 55.9%)
Figure 4 Migraine treatment practitioners.
Table 6 Migraine treatment discontinuation
Reason for discontinuation of medicine use Patient, n (%)
avoided using a medicine to treat migraines because  
of side effects
1,689 (65.4)
stopped using a medicine to treat your migraines  
because of a side effect
1,709 (66.2)
ever withheld taking medication to save for later 1,878 (73.0)
ever avoided using a medication due to cost 1,170 (45.5)
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found that migraineurs often attempt many treatments, but are 
discouraged by factors such as cost, side effects, and efficacy.17 
Even for highly efficacious, cost-effective treatments, limited 
availability of treatment or lack of treatment providers may 
prevent an individual from learning about and using low-risk 
and potentially high-benefit practices.18 The finding that a 
proportion of migraineurs found some benefit for each treat-
ment suggests that the differential effectiveness of interven-
tion may be due to idiosyncratic patient characteristics rather 
than specific treatment ineffectiveness. This emphasizes the 
need for a migraine practitioner to understand the interaction 
between psychological, social, and biological characteristics 
in the individual patient in order to accurately match a patient 
with the treatment approach most suited to their specific 
disorder pattern and personal circumstances.
The most salient difference in how migraineurs perceived 
their disorder was in the symptomatic manifestation of the 
disease. Although migraine headaches are frequently associ-
ated with aura, our sample reported migraine with aura at a 
lower level than would have been anticipated.19 Respondents 
in this study reported symptoms of nausea/vomiting and 
sensitivity to light to a higher degree than has been found 
in previous studies.20 In addition, participants in our study 
reported migraine symptoms that have not been widely 
studied to date, such as puffy eyelids and food cravings. 
The variety of symptoms reported by migraineurs attests 
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Figure 5 Migraineur satisfaction levels of medical treatment, treating physician, and non-pharmacological treatments.
Table 7 Pearson R correlations between migraine characteristics and comorbid disorders
 Negative life  
event score
Length of time since  
first migraine symptoms
Migraine symptoms 
per month (n)
Depression 0.362** 0.241** 0.253**
anxiety 0.325** 0.183** 0.230**
stroke 0.037* 0.036 0.034
epilepsy 0.040* 0.007 0.047*
hypertension 0.067** 0.113** 0.101**
Diabetes 0.034 0.054** 0.052**
Bipolar 0.077** 0.055** 0.042*
iBs 0.182** 0.156** 0.167**
chronic pain 0.346** 0.186** 0.326**
Fibromyalgia 0.189** 0.121** 0.171**
Thyroid disease 0.117** 0.110** 0.123**
chronic fatigue 0.267** 0.146** 0.253**
asthma 0.132** 0.096** 0.135**
cOPD -0.002 0.049** 0.050**
autoimmune disorder 0.087** 0.062** 0.067**
negative life event score 1 0.299** 0.519**
Length of time since first migraine symptoms 0.299** 1 0.406**
Migraine symptoms per month (n) 0.519** 0.406** 1
Notes: **Correlation is significant at the 0.01 level (two-tailed); *correlation is significant at the 0.05 level (two-tailed).
Abbreviations: cOPD, chronic obstructive pulmonary disease; iBs, irritable bowel syndrome.
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to the  individualized nature of the disorder. Further, the 
diverse manifestations of migraine symptoms lends further 
support to the view that migraines must be considered in 
the context of the individual, because different symptoms 
may have varying degrees of impact on an individual’s daily 
life. It is not unreasonable to consider symptoms such as 
vomiting and sensitivity to light as potentially eliciting a 
greater change in a sufferer’s behavior than symptoms such 
as food cravings. Different symptoms may exert  differential 
degrees of impact on a sufferer’s day-to-day life, even when 
experienced at similar frequencies, and as mentioned previ-
ously, the individual characteristics of the migraineur may 
determine the level of stress experienced as a result of these 
symptoms.
The present study probed the areas of daily life impacted 
by migraine headaches and found that these headaches 
impose a substantial biological, psychological, and social 
burden on migraineurs. The pervasive and destructive impact 
of migraine headaches on a migraineurs’ life has been well 
documented in the literature, but previous research has not 
closely examined how the stress of these negative impacts 
is moderated by the time since onset and the frequency 
of the disorder.7 The stress of chronic migraine may be a 
cyclical process which contributes to the development and 
fermentation of comorbid disorders, additional stress, and 
more migraines. This insidious cycle may be exacerbated by 
a higher number of symptoms, a higher migraine frequency, 
or pre-existing psychological or medical conditions. The 
psychological impact of migraines may inhibit the ability to 
engage in healthy practices that would reduce the prevalence 
of other disorders, decrease the use of adaptive coping with 
biological symptoms, exacerbate the pain experience, and 
may discourage adherence to treatment. Psychological dis-
tress, as well as pain, have been found to be strongly associ-
ated with development of depression or anxiety disorders,21 
and these were found to be the most common comorbid 
disorders in our study.
Table 8 analysis of variance of negative life events score triad by 
comorbid disorders
F (df-btw, df-tot) P-value η2
Depression 359.397 (1, 2,909) 0.000 0.110
anxiety 261.978 (1, 2,909) 0.000 0.083
stroke 2.432 (1, 2,909) 0.119 0.001
epilepsy 4.005 (1, 2,909) 0.045 0.001
hypertension 8.876 (1, 2,909) 0.003 0.003
Diabetes 5.675 (1, 2,909) 0.017 0.002
Bipolar 15.787 (1, 2,909) 0.000 0.005
iBs 82.398 (1, 2,909) 0.000 0.028
chronic pain 308.965 (1, 2,909) 0.000 0.096
Fibromyalgia 79.536 (1, 2,909) 0.000 0.027
Thyroid disease 30.062 (1, 2,909) 0.000 0.010
chronic fatigue 189.367 (1, 2,909) 0.000 0.061
asthma 37.651 (1, 2,909) 0.000 0.013
cOPD 0.109 (1, 2,909) 0.741 0.000
autoimmune disorder 16.681 (1, 2,909) 0.000 0.006
Length of time since first  
migraine symptoms
53.626 (4, 2,909) 0.000 0.069
Migraine symptoms per month (n) 160.685 (5, 2,909) 0.000 0.217
Abbreviations: cOPD, chronic obstructive pulmonary disease; iBs, irritable bowel 
syndrome.
Table 9 Analysis of variance for length of time since first migraine 
symptom by comorbid disorders
F (df-btw, df-tot) P-value η2
Depression 192.034 (1, 2,909) 0.000 0.062
anxiety 120.116 (1, 2,909) 0.000 0.040
stroke 4.015 (1, 2,909) 0.045 0.001
epilepsy 0.607 (1, 2,909) 0.436 0.000
hypertension 38.634 (1, 2,909) 0.000 0.013
Diabetes 7.148 (1, 2,909) 0.008 0.002
Bipolar 8.989 (1, 2,909) 0.003 0.003
iBs 73.210 (1, 2,909) 0.000 0.025
chronic pain 107.060 (1, 2,909) 0.000 0.036
Fibromyalgia 39.812 (1, 2,909) 0.000 0.014
Thyroid disease 35.871 (1, 2,909) 0.000 0.012
chronic fatigue 64.419 (1, 2,909) 0.000 0.022
asthma 30.355 (1, 2,909) 0.000 0.010
cOPD 6.326 (1, 2,909) 0.012 0.002
autoimmune disorder 12.335 (1, 2,909) 0.000 0.004
negative life event score h, M, l 107.144 (2, 2,909) 0.000 0.069
Migraine symptoms per month (n) 1028.578 (5, 2,909) 0.000 0.639
Abbreviations: cOPD, chronic obstructive pulmonary disease; iBs, irritable bowel 
syndrome; h, high; M, Medium; l, low.
Table 10 analysis of variance for migraine frequency by comor-
bid disorders
F (df-btw, df-tot) P-value η2
Depression 198.174 (1, 2,909) 0.000 0.064
anxiety 162.657 (1, 2,909) 0.000 0.053
stroke 3.373 (1, 2,909) 0.066 0.001
epilepsy 6.553 (1, 2,909) 0.011 0.002
hypertension 29.710 (1, 2,909) 0.000 0.010
Diabetes 8.025 (1, 2,909) 0.005 0.003
Bipolar 5.258 (1, 2,909) 0.022 0.002
iBs 83.857 (1, 2,909) 0.000 0.028
chronic pain 345.932 (1, 2,909) 0.000 0.106
Fibromyalgia 87.741 (1, 2,909) 0.000 0.029
Thyroid disease 44.674 (1, 2,909) 0.000 0.015
chronic fatigue 199.614 (1, 2,909) 0.000 0.064
asthma 53.744 (1, 2,909) 0.000 0.018
cOPD 7.160 (1, 2,909) 0.007 0.002
autoimmune disorder 12.975 (1, 2,909) 0.000 0.004
negative life event score h, M, l 424.841 (2, 2,909) 0.000 0.226
Length of time since first  
migraine symptoms
241.488 (4, 2,909) 0.000 0.250
Abbreviations: cOPD, chronic obstructive pulmonary disease; iBs, irritable bowel 
syndrome; h, high; M, medium; l, low.
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The high medical and personal burden reported by 
participants in the present study is significant in terms of 
emphasizing the pervasive onus that migraine headaches 
confer. This raises the question of how much medical misery 
can someone endure? Competing health priorities created 
by comorbid diseases can exacerbate the everyday cost of 
migraine symptoms by inhibiting a migraineur’s ability to 
cope biologically and psychologically. High levels of stress 
have been shown to lead to a higher prevalence of an array 
of medical and psychological disorders.22 This is true of both 
depression and anxiety, which have both been found to be 
more prevalent in the migraineur population.23 The findings of 
this study underscore the clinical importance of understand-
ing the social and psychological impact of migraine head-
aches on a migraineur. Participants found to have a higher 
degree of stress attributable to migraine symptoms were also 
found to have more comorbid disorders, and importantly, the 
most common comorbid disorders found in this sample are 
also known to be highly susceptible to stress.
 Our results highlight the clinical relevance of understand-
ing the impacts of migraine headaches on patients. Previous 
research has identified chronic psychological stress, such as 
in sufferers of a chronic disorder, to be a major suppressor of 
the human immune system.24 Healthy social relationships may 
serve as a protective factor with regard to the development 
of additional disorders in an already medically and psycho-
logically vulnerable population; however, our study sample 
reported that they experienced a variety of negative impacts to 
their social relationships due to migraine, which suggests that 
migraineurs may lack social capital when compared with other 
chronically ill groups. Use of adaptive coping strategies and 
healthy lifestyle choices can also act as protective factors for 
individuals with migraine headaches. The active engagement 
with biological, psychological, and social protective factors 
can help to reduce the “suffering” experienced by migraineurs 
and give patients more control over their headache pain and 
symptoms. Migraine practitioners should make efforts to 
understand and alleviate the impact of stress on the diverse 
areas of life in migraineurs. Where this is beyond the scope 
of the prescriber’s medical practice, they should consider 
referrals to pain psychology specialists, other mental health 
providers with specific training in the biopsychosocial models 
of pain treatment, or pain support groups.
limitations
There are some limitations to the present study. The prin-
ciple limitation is the bias, such as self-selection and self- 
identification, inherent in studying an online sample. The 
lack of information collected relating to participant race, 
education, and socioeconomic status also limit the generaliz-
ability of this study.
Conclusion
The present study extends the body of literature character-
izing treatment patterns, disorder characteristics, and dis-
ability profile in migraineurs. Migraine-associated stress 
was found to be a much more diverse experience than 
previous researchers have described. Negative social and 
personal impacts of migraines were found to be common 
in this sample. Migraineurs were found to have tried many 
different treatments but were, overall, unsatisfied with 
their efficacy. The highly personal experience of migraine 
is seen in the variety of negative life impacts secondary 
to migraine headache, diverse comorbid disorder profiles, 
and variable responses to migraine treatments. Each of 
these factors contributes to the idiosyncratic experience of 
migraine. Practitioners must understand the personal expe-
rience of each migraineur in order to match their patient to 
a treatment which will alleviate the social, biological, and 
psychological experiences of migraine headache. Migraine 
headaches were found to impart a wide variety of possible 
negative impacts on an individual’s life. Migraineurs who 
experienced more frequent symptoms tended to experience 
more negative life events related to migraine, as well as 
more medical or psychiatric comorbidities. The vast major-
ity of participants reported having seen a physician about 
their migraine headaches, with financial concerns being the 
most commonly reported reason as to why participants had 
not contacted a physician about their migraines. Similarly, 
many participants had attempted various medications in the 
past; however, these medications were frequently discon-
tinued due to side effects, and the cost of medication was 
reported to be the most common reason for discontinua-
tion. While our study sample reported common migraine 
symptoms in similar proportions to previous research, 
some symptoms reported by our study participants, such 
as puffy eyelids and food cravings, have not been exam-
ined in previous migraine research. Future research into 
migraine headaches should explore the social network 
impacts of migraine headache and examine this impact 
on the effectiveness of treatment and delivery of care for 
migraineurs.
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